LSA
NKTR icon

Leonteq Securities AG’s Nektar Therapeutics NKTR Stock Holding History

Leonteq Securities AG’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
4,400
+2,400
+120% +$176K 0.01% 493
2026
Q1 		$144K Sell
2,000
-6,000
-75% -$342K 0.01% 662
2025
Q4 		$338K Buy
+8,000
New +$448K 0.01% 548

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Leonteq Securities AG's NKTR Position: Q2 2026 in Review

Leonteq Securities AG increased its Nektar Therapeutics (NKTR) stake by 120% in Q2 2026, buying an estimated $176K and bringing the position to 4,400 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #493.

Leonteq Securities AG first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. The position peaked at $338K in Q4 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Leonteq Securities AG held 4,400 shares of Nektar Therapeutics worth $307K as of Q2 2026.
  • Leonteq Securities AG bought 2,400 Nektar Therapeutics shares in Q2 2026, an estimated $176K.
  • Nektar Therapeutics made up 0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #493 holding.
  • Leonteq Securities AG first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Leonteq Securities AG's Nektar Therapeutics position peaked at $338K in Q4 2025.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.